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Abstract Major histocompatibility complex class I B alleles, 
HLA B8, B53 and B3501 have been cloned, expressed, refolded 
and crystallized in specific complexes with a number of different 
8-mer and 9-mer peptides. For some of these crystallization was 
initiated by cross-seeding between different B allele complexes. 
All crystallize in the space group P212121, owith similar unit cell 
dimensions of approximately 52 A × 81 A × 112 A, contain 
one complex per asymmetric unit and diffract to approximately 
2.tl A resolution. 
K, T words: Protein expression; MHC class I; HLA B allele; 
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1. Introduction 
MHC class I and class II molecules are functionally and 
sl-ucturally distinct proteins encoded within the major histo- 
c~ mpatibility complex (MHC) region of chromosome 6 [1,2]. 
Recognition by the T-cell receptor (TCR) of MHC molecules 
cc, mplexed with peptide antigen is a critical event in the in- 
itiation of an immune response. Much of our understanding 
ot peptide binding to class I molecules has come from a com- 
plementary combination of analysis of X-ray crystallographic 
sl ructures and identification of naturally bound peptides [3]. 
The first class I structure, HLA A2 [4], together with subse- 
qtlent structural analysis of other human class I alleles [5-11] 
aad murine alleles [12-15] complexed with single peptides, 
revealed general principles for peptide binding to class I mo- 
lemles. These structures how that peptides are held in the 
class I binding groove at the N-and C-termini by a conserved 
network of hydrogen bonds and by the binding of conserved 
rcsidues (anchor residues) in pockets lined by polymorphic 
/~HC residues (review [16]). 
There are three major loci expressing MHC class I mole- 
c'des in man: the A, B and C alleles. The majority of extant 
structural studies have been of A alleles. To broaden our 
uaderstanding of MHC class I peptide interactions we have 
embarked on an analysis of B allele single peptide complexes. 
We have crystallized three different B alleles, HLA B8, B53 
and B3501 with various specific peptides; a total of nine dif- 
ferent peptide complexes. HLA B8 is unusual among human 
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class I molecules in having sequence motifs indicating anchor 
residues at positions 3 and 5 of the peptide (in contrast o 
anchor esidues at positions 2 and 9) [17,18]. We have crystal- 
lized B8 with an HIV-1 virus p17-3 Gag 9-mer epitope 
(GGKKKYKLK), 8-mer epitope (GGKKKYKL), and four 
naturally occurring 9-mer variants (GGKKKYRLK; 
GGKKKYQLK; GGKKRYKLK; GGRKKYKL). The first 
peptide (as 8-mer or 9-mer) causes a cytotoxic T lymphocyte 
(CTL) response whereas the presence of the variant peptides 
presented by B8 antagonises this same CTL response [19]. 
HLA B53, a common African allele, which has been shown 
to be associated with resistance to severe malaria in the Gam- 
bia [20], has been crystallized with two 9-mer peptide pitopes, 
Is6 (KPIVQYDNF) from the malaria parasite P. falciparum 
[21] and TPYDINQML from the Gag protein of HIV-2 [22]. 
The related allele HLA B3501 has also been crystallized com- 
plexed with the 8-mer nef peptide (VPLRPMTY) [23] which 
comes from a region conserved in the HIV-1 and HIV-2 gen- 
omes. 
2. Materials and methods 
2.1. Expression 
Full length B53, B35 and B8 cDNA clones were prepared from 
Hmy-B53 cell line (a gift from M. Takiguchi), B3501 T2 transfectants 
(a gift from M. Takiguchi) and an EBV transformed homozygous B8 
B cell line, respectively. The regions coding for amino acids 1-276 of 
human HLA B8 and B3501 heavy chains were amplified, by polymer- 
ase chain reaction, using the oligonucleotide primers 
5'-GCGCGGATCCCACTCCATGAGGTATTTC-3' and 5'-CCGC- 
AAGCTTTTATCATGGCTCCCATCTCAGGGT-3', respectively. 
HLA B53 heavy chain was amplified with the primers 5'-GCGC- 
GGATCCCACTCCATGAGGTATTTC-3' and 5'-CCGCAAGCT- 
TTTATCA A TGGTGGTGA TGA TGGTGTGGCTCCCATCTCAGG- 
GT-3' containing sequence coding for an additional C-terminal tag 
of six histidines (italics). The resulting fragments were digested with 
the restriction enzymes BamHI and HindlII and ligated into the T7 
expression plasmid pGMT7 (a pET derivative, [24]). The expression 
plasmid was transformed into the E. coli strain BL21(DE3)pLysS 
(Novagen) and grown at 37°C in Lurian Bertani medium containing 
100 mg/ml of ampicillin (Sigma) and 20 mg/ml of chloromphenicol 
(Sigma). Protein expression (as insoluble aggregates) was induced at 
mid-log phase (A600 = 0.64).9) with 0.4 mM isopropyl [~-D-thiogalac- 
topyranoside (IPTG) (Novabiochem) and after 4 h the cells were 
harvested. The light chain, 132-microglobulin (g2m), was provided in 
a pHN1 plasmid in the E. coli strain XA90 (a gift from D. Garboczi) 
and was similarly overexpressed as insoluble aggregates after induc- 
tion with 1 mM IPTG. Both heavy and light chain inclusion bodies 
were isolated from cell pellets by sonication, washed repeatedly in
detergent and the resulting protein solubilised in 8 M urea, 50 mM 
MES pH 6.5, 0.1 mM EDTA and 0.1 mM DTT (buffer A) according 
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Fig. 1. 15% SDS-polyacrylamide g ls showing the expression of HLA B allele heavy chain (gel 1) as a time course after IPTG induction and 
(gel 2) the relative purities of heavy chain (HC) and 62m inclusion bodies after the cells have been sonicated and washed with detergent. Lane 
1 shows Biorad low range standards with molecular weights documented on the left of the corresponding bands of the gel. Lane 2 shows the 
total cell protein (1 ml aliquots) before induction with IPTG. Lanes 3, 4 and 5 show the total cell protein at time intervals of 2, 4 and 16 h 
after induction, respectively. 
to the method escribed in [25]. In addition, the B53 heavy chain was 
further purified under denaturing conditions by binding onto a Ni 2+- 
NTA agarose column (Qiagen) and eluting with a pH gradient. B 
allele heavy chain was identified by Western blot analysis with the 
monoclonal antibody HC10 [26] and verified by N-terminal sequen- 
cing (T. Willis, Oxford Centre for Molecular Sciences, OCMS). Purity 
was assessed by running samples on 15% SDS-polyacrylamide gel 
electrophoresis in the presence of DTT and concentrations e timated 
using a BCA protein assay kit (Biorad). Peptides were synthesised on 
an applied biosystems 430A Automated Peptide Synthesiser, purified 
by HPLC reverse-phase chromatography, checked for correct mole- 
cular weight by electrospray mass spectrometry and stored as a lyo- 
philised powder (S. Shah and M. Pitkeathley, OCMS). 
2.2. Refolding and purification 
Refolding was performed by dilution of denaturing conditions at 
4°C [25]. Firstly, 25 mg of 62m in buffer A were added to 1 1 of 400 
mM L-arginine, 50 mM Tris pH 8.0, 0.1 mM EDTA, 0.1 mM PMSF 
and 0.1 mM sodium azide (refolding buffer). Secondly, 10 mg of 
peptide was dissolved into 30 mg of heavy chain, solubilised in buffer 
A, and diluted to 30 ml prior to being added into the same 1 1 volume 
of refolding buffer. The molar ratio of heavy chain :62m:peptide used 
was 1:2:10, respectively. The yield of HLA complex could be in- 
creased by starting with 3 mg of refolded 62m and 'pulsing' the re- 
folding mixture with 4 × 5 mg additions of heavy chain at 8 h inter- 
vals. After 48 h the refolding mixture was concentrated to approx. 100 
ml on a stir cell (Amicon) and further concentrated in a 10 kDa cut- 
off centriprep (Amicon). Refolded HLA complex was purified from 
the refolding mixture and buffer exchanged into 20 mM Tris pH 8.0 
on an FPLC superdex 75 prep grade gel filtration column (Pharma- 
cia). Analysis for correct folding of HLA B53 and HLA B3501 was 
carried out by capture ELISA using the conformationally dependent 
antibody, W6/32 [27], and the antibody BBM1 [28]. The antibodies 
used in the capture ELISA for HLA B8 were rat anti-HLA B and W6/ 
32 [27]. 
2.3. Crystallisation 
Crystallisation conditions for all complexes are listed in Table 1. 
Crystals were obtained by the sitting drop vapour diffusion method 
using microbridges [29]. Crystal Screens I and II (Hampton Research) 
were used to establish crystallisation conditions for the first HLA B8 
and B53 complexes (with GGKKKYKLK and KPIVQYDNF pep- 
tides, respectively). Typically, 2 ~tl of a 10 mg/ml protein solution in 
20 mM Tris, pH 8.0 (for B8) or 20 mM MES, pH 6.5 (for B53) was 
mixed in a 1 : 1 ratio with the crystallisation reservoir solution and the 
4 Ixl drops incubated at 21°C. Once an initial stock of crystals was 
established, streak seeding, with a dog whisker, between complexes 
was used to initiate crystal growth [30,31]. Crystals of the B53/ls6 
complex were nucleated by cross-seeding with crystals of B8. Like- 
wise, crystals of B3501 complexes were nucleated by cross-seeding 
with B53. Macroseeding was then used to improve the size of crystals. 
For data collection, crystals were flash-cooled in reservoir buffer 
which, in addition, contained 25% glycerol as cryoprotectant. 
2.4. Diffraction measurements and data processing 
Data for the first complex, B53/ls6, were collected at room tempera- 
ture, and required four crystals for a complete data set. Subsequent 
complexes were cryocooled (Table 1) during data collection and re- 
quired only one crystal for a complete data set. Data for both B53 
complexes and three B8 complexes were collected at station 9.6 of the 
CLRC Synchrotron Radiation Source, Daresbury (X = 0.87 A) utilis- 
ing an MAR-research imaging plate system (30 cm diameter; A. Lent- 
fer and J. Hendrix). B3501 data were collected at beamline BL1 ID13 
of the European Synchrotron Radiation Facility (ESRF) also using a 
30 cm diameter MAR-research imaging plate (X = 0.96 A). The re- 
maining three B8 complexes were collected at BL4 (ESRF) (~ = 0.76 
A) using an X-ray Image Intensifier Charged Couple Device (XRII)/ 
CCD Detector [32]. Data from the XRII/CCD Detector were first 
corrected for spatial distortion and non-uniformity of response over 
the detector system [33,34]. All diffraction data were autoindexed, 
integrated and corrected for Lorentz and polarization effects with 
the program DENZO [35] followed by scaling and merging in SCA- 
LEPACK [35]. 
3. Results and discussion 
HLA B8, B53 and B3501 heavy chains were expressed to 
high levels (80 mg/1) as inclusion bodies and detergent washed 
[25] to greater than 90% purity (Fig. 1). HLA B53 heavy 
chain, with 6 C-terminal histidines, was further purified on 
a Ni 2+-NTA agarose column and this method of affinity bind- 
ing was very effective at removing all the 'background'  cellular 
proteins, improving the refolding yield for B53. 
Since the heavy chain is only soluble in denaturing condi- 
tions, and some precipitates during the refolding, yield of 
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complex was increased by pulsing the refolding mixture with 
an additional 20 mg of heavy chain. Each refolding produces 
an excess of the soluble protein, 62m, which can be recycled 
and used in subsequent reconstitutions. Refolding by dilution 
typically allowed HLA B allele complexes to be formed with 
an estimated efficiency of 10%. Typically, 3 mg of refolded 
62m was used in addition to 30 mg of denatured 62m and 
together with heavy chain pulsing increased the yield of re- 
folded complex to 20%. An elution profile from gel filtration 
reproducibly showed three main peaks (Fig. 2) only one of 
which contained heavy chain plus B2m and showed HLA B 
allele native conformation according to the respective capture 
E~,ISA. 
Table 1 summarises the crystallisation conditions for the 
individual peptide complexes. The B8/GGKKKYKLK com- 
pl,'x formed numerous long needle-shaped crystals (Fig. 3) 
wilich were solid at one end and hollow at the other end. 
They appeared in the drops within 3-4 days and grew to 
ful  size (typically 0.1 mmX0.05 ram×0.3 ram) within 7 
&~ys. The drops, on setting up, appeared to form a heavy 
pJ ecipitate which cleared overnight leaving a very fine phase 
separation. The 3-4 day nucleation period allowed a window 
fcr streak-seeding and macroseeding techniques to be investi- 
g~ted to improve crystal quality and size. The B8/ 
GGKKKYRLK complex formed similar crystals to the first 
B~ complex in identical conditions although these crystals 
~re  not as large (typically 0.1 minx0.05 minX0.2 mm). 
Fine screening around this condition produced larger crystals 
(t/pically 0.1 minX0.05 mm×0.3 ram) with 100 mM sodium 
ci rate pH 6.5, 0.03 M ammonium acetate and 30% PEG 4000. 
Tie phase separation was less apparent in these drops and 
g~owth could only be achieved after cross-seeding with the 
f ist  B8 complex. The remaining complexes (B8/GGKKK- 
'~ QLK, B8/GGRKKYKLK, B8/GGKKRYKL and B8/GG- 
K KKYKL) all crystallized at this condition with the same 
c~ystal morphology but the two 8-mer complex crystals 
f irmed rapidly, often 'showering', without requiring seeding. 
The B53/KPIVQYDNF (ls6) complex formed flat, plate-like 
c~ystals (typically 0.1 mmx0.1 mmx0.2 mm) within 24 h. 
[ 9ng, fine needle-like crystals with multiple nucleation sites 
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Fig. 2. Chromatogram showing the elution profile of an FPLC 
superdex 75 prep grade gel filtration column. The flow rate was 
5 ml/min, typical oading sample volumes were 5 ml and the elution 
was monitored at an absorbance of 280 nm. This reproducible pro- 
file has a large, sharp peak at approx. 70 kDa (A) containing both 
heavy chain and B2m but showing no native conformation; a smal- 
ler peak at 44 kDa (B) containing refolded HLA B allele; and a lar- 
ger peak at 12 kDa containing 82m only. 
were obtained for the B53/TPYDINQML (HIV2) complex. 
Growth of B53/HIV2 crystals, similar in morphology to the 
B53/ls6 crystals, could be initiated by cross-seeding with the 
B53/ls6 or B8 complex crystals. These crystals grew as thick 
plates (typically 0.1 mm X 0.2 mm × 0.2 mm) reaching full size 
within 2 days. The B3501/VPLRPMTY (nef) complex initially 
produced flimsy thin-plate crystals but cross-seeding with B8 
or B53/ls6 crystals, led to large, thick plates. The cross-seeding 
was equally successful using B8 (21 amino acid differences 
between heavy chains) and B53 (5 amino acid differences be- 
tween heavy chains). 
Diffraction data were collected using crystals flash-cooled to 
100 K, except for the B53/ls6 complex for which data were 
collected at room temperature. The conditions for cryocooling 
are detailed in Table 1. All the complexes crystallized in clo- 
sely related units cells (space group P212121 with typical unit 
Ttble 1 
Stmmary of individual B allele complexes: conditions which produced crystal growth; cryocooling conditions; resolution; and unit cell dimen- 
si, ns 
lele Peptide Crystal growth 
condition 
B! GGKKKYKLK 30% PEG 4000, 0.1 M Na citrate, 
pH 6.5, 0.2 M NH4 acetate 
B, ~ GGKKKYQLK 30% PEG 4000, 0.1 M Na citrate, 
pH 6.5, 0.03 M NH4 acetate 
B GGKKKYRLK 30% PEG 4000, 0.1 M Na citrate, 
pH 6.5, 0.03 M NH4 acetate 
B GGKKRYKLK 30% PEG 4000, 0.1 M Na citrate, 
pH 6.5, 0.03 M NH4 acetate 
B GGRKKYKL 30% PEG 4000, 0.1 M Na citrate, 
pH 6.5, 0.03 M NH4 acetate 
B; GGKKKYKL 30% PEG 4000, 0.1 M Na citrate, 
pH 6.5, 0.03 M NH4 acetate 
Bg3 + histidine tag KPIVQYDNF 18% PEG 8000, 0.2 M Ca acetate, 
0.1 M Na cacodylate, pH 6.5 
B53 + histidine tag TPYDINQML 18% PEG 8000, 0.2 M Ca acetate, 
0.1 M Na cacodylate, pH 6.5 
B?501 VPLRPMTY 18% PEG 8000, 0.1 M Na 
cacodylate, pH 6.5 
For B8, the natural mutations of the peptide are highlighted in bold text. 
Cryo-protectant Resolution Unit cell (~,) 
(A) 
+15% glycerol 2.05 50.6, 81.4, 110.7 
+15% glycerol 2.3 50.7, 81.2, 110.6 
+15% glycerol 2.1 50.4, 80.9, 109.2 
+15% glycerol 2.2 50.6, 81.3, 110.1 
+15% glycerol 2.1 51.0, 81.6, 111.6 
+15% glycerol 2.3 50.5, 81.1, 110.2 
room temperature 2.3 51.3, 83.3, 112.4 
+25'70 glycerol 2.3 50.9, 82.5, 109.7 
+25% glycerol 2.0 51.3, 82.7, 108.6 
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0.15 mm 
Fig. 3. Photographs of (upper) a typical crystal of HLA B8 (the bar represents 0.15 mm) and (lower) the result of streak-seeding of HLA B53 
complexes by B8. 
cell dimensions a=51 ,~, b=82 ,~, c= 112 ,~,, 
a = b = c = 90 °) containing one molecule per crystallographic 
asymmetric unit. Cryocooling resulted in slight variations in 
unit cell dimensions (Table 1) for each complex. X-ray diffrac- 
tion data have been collected for all nine complexes to resolu- 
tions of at least 2.3 ,~ using synchrotron radiation. In parti- 
cular, data collected on station ID13-BL1 of the European 
Synchrotron Radiation Facility (ESRF, Grenoble, France), 
from a single, cryocooled, crystal of the B3501/nef complex, 
indicate that this crystal form is capable of ordered Bragg 
diffraction to beyond 2.0 ,~ resolution. Structure determina- 
tions of these complexes are currently underway using mole- 
cular replacement and will be reported elsewhere (Smith et al. 
and Reid et al. in preparation). 
In conclusion, we have established general protocols for the 
production and crystallisation of B allele single peptide com- 
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plexes. The uniformity of crystal form obtained for these com- 
plexes contrasts with the diversity reported for a series of A2 
single peptide complex crystals [36]. These results suggest hat 
cross-seeding leading to epitaxial growth can be a powerful 
method for driving crystallisation of closely related molecules 
inl o a similar lattice. 
Note added in proof 
For all HLA B8 complexes in which peptide used for re- 
fo ding was predominantly a 9-mer, electron density maps 
indicate that the crystals contain molecules bearing an 8-mer 
(n4nus the C-terminal ysine). Sufficient 8-mer peptide has 
been found in subsequent analysis of original samples by 
mass spectrometry to be consistent with selective crystalliza- 
ti~.n of 8-mer complexes. 
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